Cite
HARVARD Citation
Gadgeel, S. et al. (n.d.). Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders. European journal of cancer. pp. S185-. [Online].